Cargando…

Frequency-dependent effect of intravenous administration of human adipose-derived mesenchymal stem cell therapy for severe Systemic Lupus Erythematosus: A case report

Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease that involves abnormal activation of immune response, affecting multiple organs, including joints, kidneys, lungs, skin, and the hematopoietic system, thereby impairing their normal function. Despite there being no cure for SLE, Mese...

Descripción completa

Detalles Bibliográficos
Autores principales: Vij, Ridhima, Tripathy, Mallika, Kim, Hosu, Park, Hyeonggeun, Cheng, Thanh, Lotfi, Djamchid, Chang, Donna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9523069/
https://www.ncbi.nlm.nih.gov/pubmed/36187443
http://dx.doi.org/10.1016/j.jtauto.2022.100166
_version_ 1784800189522903040
author Vij, Ridhima
Tripathy, Mallika
Kim, Hosu
Park, Hyeonggeun
Cheng, Thanh
Lotfi, Djamchid
Chang, Donna
author_facet Vij, Ridhima
Tripathy, Mallika
Kim, Hosu
Park, Hyeonggeun
Cheng, Thanh
Lotfi, Djamchid
Chang, Donna
author_sort Vij, Ridhima
collection PubMed
description Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease that involves abnormal activation of immune response, affecting multiple organs, including joints, kidneys, lungs, skin, and the hematopoietic system, thereby impairing their normal function. Despite there being no cure for SLE, Mesenchymal Stem Cell (MSC) therapy offers hope for SLE patients because of its potent role in immunomodulation. Here, we report a case of a 65-year-old female battling with SLE for almost 30 years and on a treatment regimen consisting of several medications. Given the level of immunosuppression associated with conventional SLE treatments, the subject was initially enrolled as a participant in a study protocol designed to provide immune protection against COVID-19. The subject received multiple infusions of autologous Hope Biosciences adipose-derived MSCs (HB-adMSCs) which significantly improved her SLE symptoms and functionality that led the patient's physician to discontinue her Rituximab regime. Based on her response to HB-adMSC therapy, the subject was approved to receive a set of nine infusion treatments to specifically treat her SLE symptoms. Over the course of ∼ one year, the first six infusions were given on a monthly basis, while the remaining three were administered bimonthly - each with a dose of 200 million HB-adMSCs. Since the beginning of the treatment, the subject showed remarkable improvements in her SLE symptoms, as demonstrated by changes in her SF-36 questionnaire responses, Visual Analog Scale (VAS) scores, and C-Reactive Protein (CRP) measurements; however, worsening of the symptoms was noted later during treatment course (when the frequency of infusions changed to bimonthly). Although the shift in remission-relapse cycle is not fully understood, however, the data suggest that treatment frequency might be the key player. No serious adverse events occurred during the entire treatment period. Further research is needed to evaluate the results of this study.
format Online
Article
Text
id pubmed-9523069
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-95230692022-10-01 Frequency-dependent effect of intravenous administration of human adipose-derived mesenchymal stem cell therapy for severe Systemic Lupus Erythematosus: A case report Vij, Ridhima Tripathy, Mallika Kim, Hosu Park, Hyeonggeun Cheng, Thanh Lotfi, Djamchid Chang, Donna J Transl Autoimmun Research paper Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease that involves abnormal activation of immune response, affecting multiple organs, including joints, kidneys, lungs, skin, and the hematopoietic system, thereby impairing their normal function. Despite there being no cure for SLE, Mesenchymal Stem Cell (MSC) therapy offers hope for SLE patients because of its potent role in immunomodulation. Here, we report a case of a 65-year-old female battling with SLE for almost 30 years and on a treatment regimen consisting of several medications. Given the level of immunosuppression associated with conventional SLE treatments, the subject was initially enrolled as a participant in a study protocol designed to provide immune protection against COVID-19. The subject received multiple infusions of autologous Hope Biosciences adipose-derived MSCs (HB-adMSCs) which significantly improved her SLE symptoms and functionality that led the patient's physician to discontinue her Rituximab regime. Based on her response to HB-adMSC therapy, the subject was approved to receive a set of nine infusion treatments to specifically treat her SLE symptoms. Over the course of ∼ one year, the first six infusions were given on a monthly basis, while the remaining three were administered bimonthly - each with a dose of 200 million HB-adMSCs. Since the beginning of the treatment, the subject showed remarkable improvements in her SLE symptoms, as demonstrated by changes in her SF-36 questionnaire responses, Visual Analog Scale (VAS) scores, and C-Reactive Protein (CRP) measurements; however, worsening of the symptoms was noted later during treatment course (when the frequency of infusions changed to bimonthly). Although the shift in remission-relapse cycle is not fully understood, however, the data suggest that treatment frequency might be the key player. No serious adverse events occurred during the entire treatment period. Further research is needed to evaluate the results of this study. Elsevier 2022-09-23 /pmc/articles/PMC9523069/ /pubmed/36187443 http://dx.doi.org/10.1016/j.jtauto.2022.100166 Text en © 2022 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Research paper
Vij, Ridhima
Tripathy, Mallika
Kim, Hosu
Park, Hyeonggeun
Cheng, Thanh
Lotfi, Djamchid
Chang, Donna
Frequency-dependent effect of intravenous administration of human adipose-derived mesenchymal stem cell therapy for severe Systemic Lupus Erythematosus: A case report
title Frequency-dependent effect of intravenous administration of human adipose-derived mesenchymal stem cell therapy for severe Systemic Lupus Erythematosus: A case report
title_full Frequency-dependent effect of intravenous administration of human adipose-derived mesenchymal stem cell therapy for severe Systemic Lupus Erythematosus: A case report
title_fullStr Frequency-dependent effect of intravenous administration of human adipose-derived mesenchymal stem cell therapy for severe Systemic Lupus Erythematosus: A case report
title_full_unstemmed Frequency-dependent effect of intravenous administration of human adipose-derived mesenchymal stem cell therapy for severe Systemic Lupus Erythematosus: A case report
title_short Frequency-dependent effect of intravenous administration of human adipose-derived mesenchymal stem cell therapy for severe Systemic Lupus Erythematosus: A case report
title_sort frequency-dependent effect of intravenous administration of human adipose-derived mesenchymal stem cell therapy for severe systemic lupus erythematosus: a case report
topic Research paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9523069/
https://www.ncbi.nlm.nih.gov/pubmed/36187443
http://dx.doi.org/10.1016/j.jtauto.2022.100166
work_keys_str_mv AT vijridhima frequencydependenteffectofintravenousadministrationofhumanadiposederivedmesenchymalstemcelltherapyforseveresystemiclupuserythematosusacasereport
AT tripathymallika frequencydependenteffectofintravenousadministrationofhumanadiposederivedmesenchymalstemcelltherapyforseveresystemiclupuserythematosusacasereport
AT kimhosu frequencydependenteffectofintravenousadministrationofhumanadiposederivedmesenchymalstemcelltherapyforseveresystemiclupuserythematosusacasereport
AT parkhyeonggeun frequencydependenteffectofintravenousadministrationofhumanadiposederivedmesenchymalstemcelltherapyforseveresystemiclupuserythematosusacasereport
AT chengthanh frequencydependenteffectofintravenousadministrationofhumanadiposederivedmesenchymalstemcelltherapyforseveresystemiclupuserythematosusacasereport
AT lotfidjamchid frequencydependenteffectofintravenousadministrationofhumanadiposederivedmesenchymalstemcelltherapyforseveresystemiclupuserythematosusacasereport
AT changdonna frequencydependenteffectofintravenousadministrationofhumanadiposederivedmesenchymalstemcelltherapyforseveresystemiclupuserythematosusacasereport